{"id":4911,"date":"2023-07-31T14:33:58","date_gmt":"2023-07-31T14:33:58","guid":{"rendered":"https:\/\/wapcpharm.org\/journal\/?p=4911"},"modified":"2023-08-03T14:44:01","modified_gmt":"2023-08-03T14:44:01","slug":"west-african-journal-of-pharmacy-2015-26-2-43-51","status":"publish","type":"post","link":"https:\/\/wapcpharm.org\/journal\/west-african-journal-of-pharmacy-2015-26-2-43-51\/","title":{"rendered":"West African Journal of Pharmacy (2015) 26 (2) 43-51"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Compliance of healthcare providers with National treatment guidelines for HIV\/AIDS.<\/b><\/p>


<\/b><\/p>\n

Obiageri O. Obodozie-Ofoegbu, Valentine O.O Adegoke , Olubukola A. Odeniran Anita M. Fanto<\/span>
<\/p>


<\/span><\/p>\n

1 Department of Medicinal Chemistry and Quality Control, National Institute for<\/p>\n

Pharmaceutical Research and Development (NIPRD), Abuja,<\/p>\n

 <\/p>\n

2NIPRD Reseach Clinic, National Institute for Pharmaceutical Research and Development (NIPRD), Abuja.<\/span><\/p>\n

 <\/p>\n

Corresponding author: Valentine Adegoke<\/p>\n

Email: funmbi2005@yahoo.com Phone: +234 703 8930 984, +234 802 2402 470<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

ABSTRACT<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Background: <\/b>Evidence had shown that low compliance with treatment guidelines by healthcare providers\u00a0may result in incomplete care of patients thereby defeating the aim of HIV disease management and control.<\/span><\/p>

Objectives: <\/b>This study was conducted to compare the compliance of a site ART treatment team with the\u00a0National Guidelines’ recommendation on criteria for treatment initiation and regimen change among\u00a0<\/span>HIV\/AIDS experienced patients.<\/span><\/p>

Methods:<\/b> In a retrospective observational double cohort study, the medical records of all adults HIV\/AIDS\u00a0positive and treatment experienced patients (N=267) whose ART regimen were either substituted or\u00a0<\/span>switched between January 2008 and June 2009 were evaluated for the fulfilment of criteria required before\u00a0<\/span>treatment initiation and change of therapy.<\/span><\/p>

Results:<\/b> The level of compliance with guidelines’ recomendations for therapy initiation ranged from 0% –\u00a084.3% (mean= 31.4%; median = 23.2%; SD =21.5%) while compliance with guidelines’ recommendations for\u00a0<\/span>regimen change ranged from 0% – 61.4% (mean= 31.4%; median = 3.8%; SD =21.5%). There was 100% and\u00a0<\/span>89.2% compliance with ‘what to start’ and ‘when to start’ respectively.<\/span><\/p>

Conclusions:<\/b> Majority of the patients were given appropriate ART regimen at the right time based on the\u00a0guideline recommendations but compliance with guideline’s recommendations for therapy change was\u00a0<\/span>poor. The extent of compliance with guideline’s recommendations is critical to success of HIV\/AIDS control\u00a0<\/span>programme.<\/span><\/p>

Key words:<\/b> treatment-guideline, HIV\/AIDS, compliance, antiretroviral-therapy, healthcare-providers.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tDownload <\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Compliance of healthcare providers with National treatment guidelines for HIV\/AIDS. Obiageri O. Obodozie-Ofoegbu, Valentine O.O Adegoke , Olubukola A. Odeniran Anita M. Fanto 1 Department of Medicinal Chemistry and Quality Control, National Institute for Pharmaceutical Research and Development (NIPRD), Abuja,   2NIPRD Reseach Clinic, National Institute for Pharmaceutical Research and Development (NIPRD), Abuja.   Corresponding […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[224],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/4911"}],"collection":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/comments?post=4911"}],"version-history":[{"count":4,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/4911\/revisions"}],"predecessor-version":[{"id":4916,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/4911\/revisions\/4916"}],"wp:attachment":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/media?parent=4911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/categories?post=4911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/tags?post=4911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}